Daily Insider Ratings Round Up 4/9/20

InsiderInsights’ Daily Round Up articles rate the “Significance” of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the “Significance” of an insider transaction, however, and often not even the most important one.

When a new insider transaction occurs, our programs mathematically score the significance of the company’s three-month insider profile based on numerous criteria programmed into our expert system.

Stocks that achieve an InsiderInsights Company Rating of “Significant” and “Leaning” Bullish or Bearish have been independently validated to generate alpha as a group and should be considered by investors looking for new long and short investments.

Seasonal Note: Insider filing volumes are waning, as companies close trading windows to insiders until after March-quarter financials are released. Insider trades usually pick up again in May, but it will be interesting to see if the immense market sell-off changes executives’ behavior during the normally slower month of April.

———————-

On Today’s Tables:

Insider trades were rated Significant at:

• NGM Biopharmaceuticals (NGM);
• Myovant Sciences (MYOV);
• Mersana Therapeutics (MRSN); and
• Hersha Hospitality Trust (HT).

Insider trades were rated Nearly Significant at:

• Idera Pharm (IDRA);
• SunPower (SPWR);
• Franchise (FRG); and
• Bank of NY (BK).

Insider trades were considered Insignificant at:

• Zscaler (ZS);
• Zoom Video Communications (ZM);
• Uber Technologies (UBER);
• Intel (INTC);
• Alector (ALEC); and
• Apple (AAPL).

There is a Conflicted Insider Signal (both purchases & sales) at:

• Turning Point Brands (TPB);
• Centene (CNC); and
• Credit Acceptance (CACC).

---

Insider Purchases

#:	Filer Name	Insider Titles	Company Name	Ticker	TransType	Dollar Value
1	Hack Andrew A F	DIR	Mersana Therapeutics	MRSN	B	$20,649,462
2	B Riley Financial	BO	Franchise	FRG	JB*	$8,784,477
3	Pillar Invest	BO	Idera Pharm	IDRA	JB*	$4,620,062
4	Column	BO	NGM Biopharmaceuticals	NGM	B	$3,366,800
5	Mott David M	DIR	Mersana Therapeutics	MRSN	B	$3,010,769
6	Total S A	DIR, BO	SunPower	SPWR	B	$2,943,752
7	Standard Diversified	BO	Turning Point Brands	TPB	JB*	$2,824,433
8	Shah Jay H	CEO, DIR	Hersha Hospitality Trust	HT	JB*	$1,693,135
9	Goeddel David V	DIR, BO	NGM Biopharmaceuticals	NGM	B	$1,683,400
10	Sumitomo Chemical	BO	Myovant Sciences	MYOV	AB	$1,171,303

Insider Sales

#:	Filer Name	Insider Titles	Company Name	Ticker	TransType	Dollar Value
1	Berkshire Hathaway	BO	Bank of NY	BK	S	$30,871,102
2	Yuan Eric S	CEO, DIR, BO	Zoom Video Communications	ZM	AS	$16,548,462
3	Camp Garrett	DIR	Uber Technologies	UBER	AS	$13,779,684
4	Foss Donald A	BO	Credit Acceptance	CACC	S	$11,895,799
5	Maestri Luca	VP, CFO	Apple	AAPL	AS	$10,858,445
6	Orbimed Advisors	BO	Alector	ALEC	S	$9,019,571
7	Canessa Remo	CFO	Zscaler	ZS	AS	$7,150,000
8	Standard General	BO	Turning Point Brands	TPB	JS*	$2,824,433
9	Rodgers Steven Ralph	VP, GC	Intel	INTC	AS	$2,293,200
10	Burdick Kenneth A	VP	Centene	CNC	AS	$2,220,360

Source: InsiderInsights.com. Key to Insider Title and Trans Type Codes: B = Open-market Buy; AB = 10b5-1 (automatic) Buy; JB* = Buy indicated as being open-market but not confirmed by trading price range and volume for the session. S = Open-market Sale; AS = 10b5-1 (automatic) Sale; JS* = Sale indicated as being open-market but not confirmed by trading price range and volume for the session.

Did you miss our Previous Daily Round Up?

If you’re serious about using insider data in your investment process, you can’t find a better source of investment ideas (or a better value!) than our Daily Ratings Reports!

Trials have been turned off to our MarketPlace after we uploaded 2 Historically HUGE Bonus Reports containing all the active, “Significant” insider signals generated during the March Market Madness. They are just too valuable to simply give away to triallers with no intention of subscribing. So Subscribe Now, and be prepared when the market next opens!

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.